INVENTIVA SA

Inventiva’s 7.59% rally fuels optimism over its Phase IIb NASH drug and strong partner network, but 200‑day SMA signals a possible pullback if milestones miss. Investors weigh high upside against clinical volatility.

Inventiva SACA’s 7.6% rally reflects speculative optimism on its Phase IIb NASH trial, but investors face clinical risk and low valuation against peers.

Inventiva (IVA.PA) slips 0.73% as investors await breakthrough clinical data, with a robust pipeline and top‑tier partnerships poised to drive future upside.